Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: A randomized, placebo-controlled trial

Annals of Internal Medicine

Volumn 153, Issue 10, 2010, Pages 621-632

  Idan, Amanda ^a,b   Griffiths, Kaye A ^a,b   Harwood, D Tim ^a,c   Seibel, Markus J ^a,b   Turner, Leo ^a,b   Conway, Ann J ^a,b   Handelsman, David J ^a,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

^c CAWTHRON INSTITUTE   (New Zealand)

^d ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA ANDROSTANEDIOL; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; CREATININE; ESTRADIOL; FOLLITROPIN; HEMOGLOBIN; LUTEINIZING HORMONE; PLACEBO; PROCOLLAGEN C PROTEINASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY FAT; BONE DENSITY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMATOCRIT; HIP; HUMAN; LEAN BODY WEIGHT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SPINE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION;

EID: 78751684940     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-10-201011160-00004     Document Type: Article

References (62)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9. [PMID: 6206240]
2. Oesterling JE. Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl. 1996;6:67-73. [PMID: 8630233]
3. DiSantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int. 2006;97:1007-16. [PMID: 16542339]
4. Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009;55:129-36. [PMID: 19886768]
5. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003; 349:2387-98. [PMID: 14681504]
6. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008;102:981-6. [PMID: 18549433]
7. Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, et al. Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989;320:1120-4. [PMID: 2469015] (Pubitemid 19114390)
8. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006;97 Suppl 2:3-6; discussion 21-2. [PMID: 16507045]
9. McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier KH, Risbridger GP. Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia. Endocrinology. 2007;148:566-74. [PMID: 17068134] (Pubitemid 46143161)
10. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci U S A. 2002;99:13589-94. [PMID: 12370428] (Pubitemid 35221316)
11. Swerdloff RS, Wang C. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent. Baillieres Clin Endocrinol Metab. 1998;12:501-6. [PMID: 10332569] (Pubitemid 29121663)
12. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab. 2001;86: 4078-88. [PMID: 11549629] (Pubitemid 32848516)
13. Kunelius P, Lukkarinen O, Hannuksela ML, Itkonen O, Tapanainen JS. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467-72. [PMID: 11932266] (Pubitemid 34615223)
14. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009;12:232-40. [PMID: 19357508]
15. Griffiths KA, Ly LP, Jin B, Chan L, Handelsman DJ. Transperineal ultrasound for measurement of prostate volume: validation against transrectal ultrasound. J Urol. 2007;178:1375-9; discussion 1379-80. [PMID: 17706715]
16. Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta. 2009;409:78-84. [PMID: 19747904]
17. Guo T, Taylor RL, Singh RJ, Soldin SJ. Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. Clin Chim Acta. 2006;372:76-82. [PMID: 16707118] (Pubitemid 44286760)
18. Guo T, Gu J, Soldin OP, Singh RJ, Soldin SJ. Rapid measurement of estrogens and their metabolites in human serum by liquid chromatographytandem mass spectrometry without derivatization. Clin Biochem. 2008;41:736-41. [PMID: 18358240]
19. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37:224-30. [PMID: 11153743]
20. Lukaski HC. Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr. 1987;46:537-56. [PMID: 3310598]
21. O'Driscoll SW, Horii E, Ness R, Cahalan TD, Richards RR, An KN. The relationship between wrist position, grasp size, and grip strength. J Hand Surg Am. 1992;17:169-77. [PMID: 1538102]
22. Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51:1167-70. [PMID: 9817134] (Pubitemid 28527172)
23. Cockett AT, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, et al. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands: Scientific Communications International; 1993.
24. Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol. 1999;52:643-51. [PMID: 10391658] (Pubitemid 29281660)
25. Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C. A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl. 2003;24:688-98. [PMID: 12954659] (Pubitemid 38133070)
26. Little R, Rubin D. Statistical Analysis With Missing Data. 2nd ed. Hoboken, NJ: J Wiley; 2002.
27. Kenward MG. Selection models for repeated measurements with nonrandom dropout: an illustration of sensitivity. Stat Med. 1998;17:2723-32. [PMID: 9881418]
28. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol. 1992;88:15-22. [PMID: 1334007]
29. Zhou ZX, Lane MV, Kemppainen JA, French FS, Wilson EM. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol. 1995;9:208-18. [PMID: 7776971]
30. Kumar N, Crozat A, Li F, Catterall JF, Bardin CW, Sundaram K. 7alphamethyl-19-nortestosterone, a synthetic androgen with high potency: structureactivity comparisons with other androgens. J Steroid Biochem Mol Biol. 1999; 71:213-22. [PMID: 10704910] (Pubitemid 30125684)
31. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-92. [PMID: 14749457] (Pubitemid 38133769)
32. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003;24: 299-311. [PMID: 12721204] (Pubitemid 39571784)
33. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ. Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19- nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. J Clin Endocrinol Metab. 1998;83:4212-9. [PMID: 9851754] (Pubitemid 29100112)
34. Kumar N, Didolkar AK, Monder C, Bardin CW, Sundaram K. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology. 1992;130:3677-83. [PMID: 1597164]
35. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol. 2008;110:214-22. [PMID: 18555683] (Pubitemid 351799973)
36. Attardi BJ, Page ST, Hild SA, Coss CC, Matsumoto AM. Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities. J Steroid Biochem Mol Biol. 2010;118:151-61. [PMID: 19941958]
37. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with lateonset hypogonadism: a randomized controlled trial. JAMA. 2006;296:2351-61. [PMID: 17105798] (Pubitemid 44749363)
38. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39-52. [PMID: 18167405]
39. Tong S, Cardinal HN, McLoughlin RF, Downey DB, Fenster A. Intra- and inter-observer variability and reliability of prostate volume measurement via two-dimensional and three-dimensional ultrasound imaging. Ultrasound Med Biol. 1998;24:673-81. [PMID: 9695270] (Pubitemid 28285203)
40. Stanczyk FZ, Cho MM, Endres DB, Morrison JL, Patel S, Paulson RJ. Limitations of direct estradiol and testosterone immunoassay kits. Steroids. 2003;68:1173-8. [PMID: 14643879] (Pubitemid 37476355)
41. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, et al. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem. 2003;49:1381-95. [PMID: 12881456] (Pubitemid 36900626)
42. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004;89:534-43. [PMID: 14764758] (Pubitemid 38269854)
43. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab. 2005; 90:5928-36. [PMID: 16118337] (Pubitemid 41606507)
44. Hsing AW, Stanczyk FZ, Bélanger A, Schroeder P, Chang L, Falk RT, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev. 2007;16:1004-8. [PMID: 17507629] (Pubitemid 46910104)
45. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001;58:5-16. [PMID: 11750242]
46. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994;40:341-9. [PMID: 7514512] (Pubitemid 24194627)
47. Meikle AW, Stephenson RA, Lewis CM, Middleton RG. Effects of age and sex hormones on transition and peripheral zone volumes of prostate and benign prostatic hyperplasia in twins. J Clin Endocrinol Metab. 1997;82:571-5. [PMID: 9024256]
48. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf). 2001;54:437-45. [PMID: 11318778] (Pubitemid 34204179)
49. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab. 2003;88: 2049-54. [PMID: 12727953] (Pubitemid 36549876)
50. Henry MJ, Pasco JA, Korn S, Gibson JE, Kotowicz MA, Nicholson GC. Bone mineral density reference ranges for Australian men: Geelong Osteoporosis Study. Osteoporos Int. 2010;21:909-17. [PMID: 19707703]
51. Khosla S, Melton LJ 3rd, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab. 2002;87:1443-50. [PMID: 11932262] (Pubitemid 34615219)
52. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003;88:204-10. [PMID: 12519853] (Pubitemid 36115166)
53. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553-60. [PMID: 11120762] (Pubitemid 32038592)
54. Santen RJ, Brodie H, Simpson ER, Siiteri PK, Brodie A. History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev. 2009;30:343-75. [PMID: 19389994]
55. Roselli CE, Resko JA. Cytochrome P450 aromatase (CYP19) in the nonhuman primate brain: distribution, regulation, and functional significance. J Steroid Biochem Mol Biol. 2001;79:247-53. [PMID: 11850231]
56. Seibel MJ, Cosman F, Shen V, Gordon S, Dempster DW, Ratcliffe A, et al. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res. 1993; 8:881-9. [PMID: 8352070] (Pubitemid 23191642)
57. Martin T, Gooi JH, Sims NA. Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr. 2009;19:73-88. [PMID: 19191758]
58. Gray PB, Singh AB, Woodhouse LJ, Storer TW, Casaburi R, Dzekov J, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005;90:3838-46. [PMID: 15827094] (Pubitemid 41058141)
59. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90:678-88. [PMID: 15562020] (Pubitemid 40279179)
60. Storer TW, Woodhouse L, Magliano L, Singh AB, Dzekov C, Dzekov J, et al. Changes in muscle mass, muscle strength, and power but not physical function are related to testosterone dose in healthy older men. J Am Geriatr Soc. 2008;56:1991-9. [PMID: 18795988]
61. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93:914-9. [PMID: 18160461] (Pubitemid 351398573)
62. Handelsman DJ, Liu PY. Andropause: invention, prevention, rejuvenation. Trends Endocrinol Metab. 2005;16:39-45. [PMID: 15734143]